INT26706

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.68
First Reported 1989
Last Reported 2008
Negated 0
Speculated 0
Reported most in Body
Documents 8
Total Number 8
Disease Relevance 3.32
Pain Relevance 2.12

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

lipid binding (CD36) transport (CD36) small molecule metabolic process (CD36)
cell adhesion (CD36) Golgi apparatus (CD36) plasma membrane (CD36)
Anatomy Link Frequency
macrophages 2
fat cell 2
CD36 (Homo sapiens)
Pain Link Frequency Relevance Heat
antagonist 9 100.00 Very High Very High Very High
Adalimumab 438 99.98 Very High Very High Very High
Potency 3 97.88 Very High Very High Very High
Inflammation 116 96.40 Very High Very High Very High
Clonidine 1 92.80 High High
adenocard 1 92.28 High High
agonist 4 87.48 High High
aspirin 18 84.32 Quite High
dexamethasone 12 82.76 Quite High
cytokine 42 79.04 Quite High
Disease Link Frequency Relevance Heat
Obesity 21 100.00 Very High Very High Very High
INFLAMMATION 137 96.40 Very High Very High Very High
Apoptosis 12 94.24 High High
Cancer 93 90.12 High High
Increased Venous Pressure Under Development 74 78.44 Quite High
Recurrence 2 78.24 Quite High
Metastasis 9 77.48 Quite High
Necrosis 25 75.00 Quite High
Atherosclerosis 42 74.36 Quite High
Repression 12 72.80 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
This is in accordance with previous studies showing that products derived from lipid peroxidation induce transcription of CD36 in murine macrophages by activating transcription factors, such as Nrf2 [21,38].
Positive_regulation (induce) of Transcription (transcription) of CD36 in macrophages
1) Confidence 0.68 Published 2007 Journal Arthritis Res Ther Section Body Doc Link PMC1906797 Disease Relevance 0.13 Pain Relevance 0.22
reduced CD36 mRNA expression (-72%, 0.28 ± 0.05, p = 0.002), while rosiglitazone increased CD36 mRNA expression (+46%, 1.46 ± 0.2, p = 0.02).
Positive_regulation (increased) of Transcription (expression) of CD36
2) Confidence 0.68 Published 2007 Journal Arthritis Res Ther Section Body Doc Link PMC1906797 Disease Relevance 0.07 Pain Relevance 0
For alpha-2 antagonists, the potency order was: yohimbine greater than idazoxan greater than SK&F-86,466 much greater than benextramine; 3) a description of the impact of benextramine (irreversible alpha-1/alpha-2 antagonist) on human fat cell alpha-2 adrenergic receptors and on human fat cell function; the drug inactivates the alpha-2 adrenergic receptors with a minor impact on beta adrenergic receptors and without noticeable alterations of fat cell function as assessed by preservation of beta adrenergic and Al-adenosine receptor-mediated lipolytic responses; and 4) a definition of the relationship existing between alpha-2 adrenergic receptor occupancy, inhibition of adenylate cyclase activity and antilipolysis with full and partial agonists.
Positive_regulation (inactivates) of Transcription (description) of fat in fat cell associated with adenocard, antagonist, obesity, agonist and potency
3) Confidence 0.49 Published 1989 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 2566681 Disease Relevance 0.67 Pain Relevance 0.49
monoclonal antibody, adalimumab, independently increases both CD36 membrane expression and mRNA expression.
Positive_regulation (increases) of Transcription (expression) of CD36 associated with adalimumab
4) Confidence 0.46 Published 2007 Journal Arthritis Res Ther Section Body Doc Link PMC1906797 Disease Relevance 0.81 Pain Relevance 0.31
g/ml) increased CD36 mRNA expression by 96% (1.96 ± 0.2, p = 0.02) in comparison to basal conditions.


Positive_regulation (increased) of Transcription (expression) of CD36
5) Confidence 0.46 Published 2007 Journal Arthritis Res Ther Section Body Doc Link PMC1906797 Disease Relevance 0 Pain Relevance 0.28
In contrast, adalimumab increases both CD36 membrane expression and mRNA expression.
Positive_regulation (increases) of Transcription (expression) of CD36 associated with adalimumab
6) Confidence 0.46 Published 2007 Journal Arthritis Res Ther Section Abstract Doc Link PMC1906797 Disease Relevance 0.58 Pain Relevance 0.45
Adalimumab independently increases both CD36 membrane expression and mRNA expression.
Positive_regulation (increases) of Transcription (expression) of CD36 associated with adalimumab
7) Confidence 0.46 Published 2007 Journal Arthritis Res Ther Section Body Doc Link PMC1906797 Disease Relevance 0.07 Pain Relevance 0.36
by enhancement of CD36 gene transcription [74].
Positive_regulation (enhancement) of Transcription (transcription) of CD36
8) Confidence 0.27 Published 2008 Journal PPAR Research Section Body Doc Link PMC2366048 Disease Relevance 0.98 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox